Execution Problems Emerge

Drug manufacturing reshoring is capital-intensive and heavily regulated, making delays plausible even with federal support. Anthea could face FDA validation, construction, labor, or input-cost constraints that reduce the credibility of a fast offshoring reversal.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.